Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 184.108.40.206) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 – Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 18.104.22.168) – Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).
Get a PDF Sample of Market Report @: http://www.orbisresearch.com/contacts/request-sample/323718
Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Reasons to buy this Report :
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 126.96.36.199)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 188.8.131.52) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Purchase a copy of Report@: http://www.orbisresearch.com/contact/purchase/323718
Astellas Pharma Inc
Blueprint Medicines Corp
Bristol-Myers Squibb Company
Eisai Co Ltd
Eli Lilly and Company
H3 Biomedicine Inc
Ionis Pharmaceuticals Inc
Johnson & Johnson
NGM Biopharmaceuticals Inc
Principia Biopharma Inc
Tasly Pharmaceutical Group Co Ltd
Vichem Chemie Research Ltd.,
Some Points From List Of Tables :
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019